Globus Medical Reports Record Sales Growth for 2024

Globus Medical

AUDUBON, PA — Globus Medical, Inc. (NYSE: GMED) has reported impressive preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The medical device company anticipates fourth-quarter sales of $657.0 million, reflecting a 6.6% increase compared to the same period in 2023. Full-year 2024 revenue is projected at $2.52 billion, a substantial 60.6% increase over the prior year.

This growth comes during the company’s first full year following its merger with NuVasive, a strategic move that has significantly strengthened its position in the spine and musculoskeletal technology markets.

“2024 was an exceptional year of execution and achievement for Globus Medical,” said Dan Scavilla, president and CEO. “With the NuVasive merger, we believe we created the strongest sales force and best product offering in the spine industry while maintaining our lead as the most innovative company backed up by a strong patent portfolio. We remain focused on product innovation, superior customer service, and operational excellence as we continue to advance patient care.”

The year also saw a record number of new product launches and the company’s highest placements of Enabling Technology devices, all while accelerating merger synergies. Globus Medical has set its sights on continued growth in 2025, with plans to introduce more products across its portfolio and focus on advancing its presence in the broader musculoskeletal market.

“Our fourth quarter results demonstrated sustained growth and execution,” added Keith Pfeil, COO and CFO. “We seek to build upon these successes in 2025, driving growth across our portfolio while advancing patient care and creating value for our shareholders.”

READ:  Cencora Expands Specialty Leadership with $4.4 Billion Acquisition of Retina Consultants of America

Looking ahead, Globus Medical has established a revenue guidance range of $2.66 billion to $2.69 billion for 2025 and projected fully diluted non-GAAP earnings per share of $3.40 to $3.50.

Final numbers for the fourth quarter and full year 2024 will be released on February 20, 2025, after the market close. These preliminary results are subject to change pending the company’s final analysis.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.